Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2024

Open Access 01-12-2024 | Osteosarcoma | Retraction Note

Retraction Note: Down-regulation of LINC00472 promotes osteosarcoma tumorigenesis by reducing FOXO1 expressions via miR-300

Authors: Jingwei Zhang, Jieyuan Zhang, Dong Zhang, Weifeng Ni, Haijun Xiao, Bizeng Zhao

Published in: Cancer Cell International | Issue 1/2024

Login to get access

Excerpt

Retraction Note: Cancer Cell International (2020) 20:100 …
Metadata
Title
Retraction Note: Down-regulation of LINC00472 promotes osteosarcoma tumorigenesis by reducing FOXO1 expressions via miR-300
Authors
Jingwei Zhang
Jieyuan Zhang
Dong Zhang
Weifeng Ni
Haijun Xiao
Bizeng Zhao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2024
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-024-03268-7

Other articles of this Issue 1/2024

Cancer Cell International 1/2024 Go to the issue

Correction

Correction: circular RNAs in renal cell carcinoma: from mechanistic to clinical perspective

Research

Peroxiredoxin 3 regulates breast cancer progression via ERK-mediated MMP-1 expression

Research

Immune cell infiltration and drug response in glioblastoma multiforme: insights from oxidative stress-related genes

Research

Integrated analysis reveals critical cisplatin-resistance regulators E2F7 contributed to tumor progression and metastasis in lung adenocarcinoma

Review

Antitumor mechanisms and future clinical applications of the natural product triptolide

Research

The molecular characteristics could supplement the staging system of pT2/T3N0M0 esophageal squamous cell carcinoma: a translational study based on a cohort with over 20 years of follow-up
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits